Helixgate

Helixgate

Endpoints News

Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trial

Published

on

Roche’s subsidiary Genentech has called off the late-stage development of a muscle-building drug in two rare genetic conditions, spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD).

The move raises questions about whether the drug …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Endpoints News

A week of bolt-on deals; Wave crashes on obesity data; Sanofi partners with TCE startup; and more

Published

on

Welcome back to Endpoints Weekly! Our team tracked a handful of deals announced this week as the first quarter comes to a close. Check below for a summary of those moves, including Merck’s $6.7 billion …

Continue Reading

Endpoints News

Otsuka buys Transcend Therapeutics for $700M upfront

Published

on

Otsuka is buying neuropsychiatric drugmaker Transcend Therapeutics in a deal worth roughly $1.2 billion, further bolstering a class of drugs that are supposed to provide the therapeutic benefits of psychedelics without the trip.

As part …

Continue Reading

Endpoints News

CHMP recommends subcutaneous form of Sanofi’s Sarclisa and four new drugs

Published

on

The European Medicines Agency’s human medicines committee has recommended the approval of four new drugs and a new form of Sanofi’s multiple myeloma drug.

CHMP gives its opinions on drug approvals and label expansions to …

Continue Reading
Advertisement

Trending